New study improves understanding of widespread diseases
When proteins in the brain form deposits consisting of insoluble aggregates, diseases such as Alzheimer's or Parkinson's can occur. Now a research team has come a step closer to understanding this process.
In Parkinson's disease the alpha-synuclein (α-synuclein) protein forms aggregates leading to impaired brain function and the development of the disease.
Now researchers at the University of Gothenburg and universities in Basel and Zurich have published a new study in Nature that demonstrates how a certain class of proteins can regulate and prevent α-synuclein from forming protein deposits and insoluble aggregates within healthy cells.
A breakthrough in research
Protein folding describes the process by which a protein takes on its specific three-dimensional shape, enabling the protein to fulfil its function.
Countless proteins in mammalian cells do not have a stable protein fold, despite the important functions they serve in the cells. One of these proteins is α-synuclein. In the new study, the research team could now reveal the basic process that affects how the α-synuclein protein is folded and aggregated as well as how molecular chaperones in living mammalian cells can prevent the misfolding of α-synuclein.
"A large pool of various chaperones prevents α-synuclein from forming protein aggregates in healthy cells. By studying the protein directly in mammalian cells, we have found that inhibition of chaperones leads to aggregation of α-synuclein at the amino acid level."
Disruption of the α-synuclein-chaperone interaction may be the long-sought first step that initiates the development of a-synuclein-related diseases, according to Björn Burmann and his research colleagues.
Source:
Journal reference:
Burmann, B.M., et al. (2019) Regulation of α-synuclein by chaperones in mammalian cells. Nature. doi.org/10.1038/s41586-019-1808-9.
No comments:
Post a Comment